| Literature DB >> 36065649 |
Shinae Yi1, Hyun Jung Kim2, Bon Seok Koo3, Seong Eun Lee1, Jahyun Choi4, Yea Eun Kang1.
Abstract
Entities:
Mesh:
Year: 2022 PMID: 36065649 PMCID: PMC9449111 DOI: 10.3803/EnM.2022.1536
Source DB: PubMed Journal: Endocrinol Metab (Seoul) ISSN: 2093-596X
Fig. 1.Representative images of the cell counter (LUNA-FX7™ Automated Cell Counter, Logos Biosystems). (A) Ninety-three percent viability in the normal thyroid sample from the patient with papillary thyroid microcarinoma after the dissociation protocol (50×). (B) Eighty-six percent viability in the normal thyroid sample from the patient with adenomatous goiter after the dissociation protocol (50×). (C) Ninety-one percent viability in the tumor sample from the patient with papillary thyroid carcinoma after the dissociation protocol (50×). (D) Ninety-three percent viability from the tumor samples from the patient with follicular thyroid carcinoma after the dissociation protocol (50×). (E) Eighty-four percent viability from the tumor samples from the patient with anaplastic thyroid carcinoma after the dissociation protocol (50×). (F) Eighty-six percent viability from the tumor samples from the patient with anaplastic thyroid carcinoma after the dissociation protocol (50×).